Payee Name and Address Sample Clauses
The 'Payee Name and Address' clause specifies the exact individual or entity to whom payments should be made, along with their corresponding address. In practice, this clause requires the payer to direct all payments to the named payee at the stated address, which may be a physical location or a designated bank account address. By clearly identifying the recipient and payment destination, this clause helps prevent misdirected payments and ensures that funds are delivered to the correct party, thereby reducing the risk of disputes or delays.
Payee Name and Address. Payment of the sums due under this Agreement will be made payable to (further „Payee“): 1.
Payee Name and Address. Payment of the sums due under this Agreement will be made payable to („Payee“): 1. Meno a adresa príjemcu platby: Úhrady splatné na základe tejto Zmluvy budú poukázané (komu) („príjemca platieb“): The Payee must provide CRO, in writing, full payment instructions for the payee listed above, including completion of applicable payment processing forms, before any payments can be made under the Agreement. The Payee is obligated to inform CRO, in writing, of any changes or required updates of payment instructions and/or bank details. Príjemca platieb musí písomne poskytnúť CRO úplné pokyny týkajúce sa platieb pre vyššie uvedeného príjemcu platieb vrátane vyplňovania príslušných formulárov na spracúvanie platieb predtým, ako budú poukázané akékoľvek platby vyplývajúce zo Zmluvy. Príjemnca platieb je povinný písomne informovať CRO o všetkých zmenách alebo požadovaných aktualizáciách v pokynoch týkajúcich sa platieb a/alebo bankových údajov. No other payments will be made to the Payee until the following are completed: (1) execution of the Agreement, (2) applicable EC (s) approval. If the Agreement is terminated before all payments are earned, the remainder must be returned to CRO immediately in accordance with Section 13 (Refunds) below. If Payee fails to do so, Pfizer, in its sole discretion, may apply such unearned sums to payments otherwise due in connection with Payee participation in another Pfizer study or may pursue other available remedies. Príjemcovi platieb nebudú poukázané žiadne iné platby, kým nebude vykonané: (1) uzavretie tejto Zmluvy, (2) schválenie príslušnou etickou komisiou Ak sa platnosť Zmluvy skončí pred vyčerpaním všetkých poukázaných platieb, nevyčerpaná suma sa musí okamžite vrátiť CRO v súlade s nižšie uvedeným článkom 13 (Refundácia). Ak príjemca platieb nesplní túto podmienku, Pfizer môže na základe vlastného uváženia použiť takéto nevyčerpané sumy na úhradu platieb, ktoré sú inak splatné v súvislosti s účasťou príjemcu platieb v inom klinickom skúšaní Pfizer alebo môže uplatniť iné dostupné opravné prostriedky.
Payee Name and Address. Payment of the sums due under this Agreement will be made payable to FN Brno: Payee (Institution): Fakultní nemocnice Brno The Institution must provide Pfizer, in writing, full payment instructions for the payee listed above, including completion of applicable payment processing forms, before any payments can be made under the Agreement. Forms for payment processing will be sent to XXX The Institution is obligated to inform Pfizer, in writing, of any changes or required updates of payment instructions and/or bank details. All payments will be made on a quarterly basis electronically and will be based on an invoice. An invoice will be issued by Institution based on calculation made by Pfizer, within 15 days of receipt of this calculation by the Institution (the day of receipt of calculation is also the date of taxable supply). The calculation must be provided for all items included in the budget. Calculations for all items specified in the budget will be provided by the responsible XXX. The invoice is due 45 days after delivery. In the event of payment not being made within 45 days from the date of receipt of valid invoice, the Institution is authorized to charge default interest at the statutory rate. In the event that Pfizer does not deliver the calculation to the Institution in accordance with the above mentioned schedule and/or in the event of a payment not being made within 45 days from the date of receipt of valid invoice, the Institution is entitled to suspend data entry into the database until the relevant payment has been made. The contact person for sending documents for invoicing is XXX Pfizer will make the start-up fee payment in the amount listed in Exhibit 1 before signing the Agreement on the basis of an invoice issued separately by the Institution and submission and approval of valid invoice, if required. No other payments will be made to the Institution until the following are completed: (1) execution of the Agreement, (2) submission of all regulatory documents to Pfizer, and (3) IRB approval. If the Agreement is terminated before all payments are earned, the remainder will be to Pfizer upon its request sent to: XXX
Payee Name and Address. Payment of the sums due under this Agreement will be made payable to: 1. Jména a adresa příjemce: Platba částek splatných podle této smlouvy bude poukázána: PI Name / Jméno hlavního zkoušejícího: XXXXXXXXX Pfizer assigned Site ID / ID pracoviště přiřazené společností Pfizer: XXXXXXXXX Payee / Příjemce: XXXXXXXXX ▇▇▇▇▇’▇ Address / Adresa příjemce: XXXXXXXXX ▇▇▇▇▇’▇ Phone Number / Telefonní číslo příjemce: XXXXXXXXX ▇▇▇▇▇’▇ AP/Payment Contact Email address / Kontaktní e-mailová adresa příjemce pro AP/platbu: XXXXXXXXX VAT ID Number / DIČ: XXXXXXXXX Bank Name/Název banky: XXXXXXXXX Bank Address/Adresa banky: XXXXXXXXX Account Number/Číslo účtu: XXXXXXXXX IBAN: XXXXXXXXX SWIFT Code/Kód XXXXXXXXX Institution / Instituce: Fakultní nemcnice u sv. Anny v Brně Pfizer assigned Site ID / ID pracoviště přiřazené společností Pfizer: XXXXXXXXX Payee / Příjemce: Fakultní nemocnice u sv. Anny v Brně ▇▇▇▇▇’▇ Address / Adresa příjemce: ▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇ ▇▇▇ ▇▇ ▇▇▇▇▇’▇ Phone Number / Telefonní číslo příjemce: XXXXXXXXX ▇▇▇▇▇’▇ AP/Payment Contact Email address / Kontaktní e-mailová adresa příjemce pro AP/platbu: XXXXXXXXX VAT ID Number / DIČ: CZ00159816 Bank Name/Název banky: Česká národní banka Bank Address/Adresa banky: ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇ ▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ / ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Account Number/Číslo účtu: 20001-71138621/0710 IBAN: ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ SWIFT Code/Kód ▇▇▇▇▇▇▇▇ Reference number / Variabilní symbol: Invoice number / Číslo faktury The Institution and Principal Investigator must Instituce a Hlavní zkoušející jsou povinni provide CRO, in writing, full payment instructions for the payee listed above, including completion of applicable payment processing forms, before any payments can be made under the Agreement. The Institution Principal Investigator is obligated to inform CRO, in writing, of any changes or required updates of payment instructions and/or bank details. poskytnout CRO kompletní písemné pokyny k platbě hrazené výše uvedenému příjemci včetně vyplnění příslušného formuláře pro zpracování plateb a teprve poté bude možné provést platby podle této smlouvy. Instituce a Hlavní zkoušející jsou povinni písemně informovat CRO o všech změnách nebo požadovaných aktualizacích pokynů k platbě nebo bankovních údajů. CRO will make the start-up fee payments (Start- up fee, Laboratory start-up fee, Pharmacy Start-up fee) in the amounts listed in Exhibit 1 after execution of this Agreement after the invoice was issued by the Institution. No other payments wi...
Payee Name and Address. Payment of the sums due under this Agreement will be made payable to: 1. Názov a adresa príjemcu: Platba splatných súm podľa tejto Zmluvy sa uskutoční na adresu: █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ █████ Exhibit 1 to the Attachment / Doložka č. 1 k prílohe A
I. Treatment Arm / Liečebné rameno I. Kontrolné rameno EQUIPMENT AND MATERIALS VYBAVENIE A MATERIÁLY CRO or Pfizer will provide the equipment identified below (“CRO Equipment”) for use by Institution in the conduct or reporting of the Study: None CRO alebo spoločnosť Pfizer poskytne vybavenie uvedené nižšie (ďalej „vybavenie CRO”), ktoré bude inštitúcia používať pri vykonávaní klinického skúšania a hlásení výsledkov: Žiadne CRO or Pfizer will provide the proprietary materials owned or licensed by CRO or Pfizer and identified below (“CRO Materials”) for use by Institution in the conduct or reporting of the Study. CRO alebo spoločnosť Pfizer poskytne materiály duševného vlastníctva, ktoré vlastní alebo má na ne licenciu CRO alebo spoločnosti Pfizer uvedené nižšie (ďalej „materiály CRO”), ktoré bude inštitúcia používať pri vykonávaní klinického skúšania a hlásení výsledkov.